Psychiatry and Neurology, Neurology · Mobile, AL
NPI
1386625507
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1601 Center Street, Ste. 2s
Mobile, AL, 36604
Phone (251) 660-5108
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
104 services
Medicare patients, 2024
79
Average age 60
Drug cost, 2024
$1.1M
1,295 prescriptions
Company payments, 2025
$4,008
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dean K Naritoku was code 99215 (office e&m - established), 25 times for 21 patients. In total Dean K Naritoku billed 104 services in 13 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 25 | 21 | $114.29 | $2,857 |
| 99214 Office E&M - Established | Office | 23 | 22 | $54.85 | $1,262 |
| 99205 Office E&M - New | Office | 12 | 12 | $126.37 | $1,516 |
By year: 2022 $13K for 158 services; 2023 $13K for 130 services; 2024 $10K for 104 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dean K Naritoku prescribed most often to Medicare patients was Levetiracetam, with 159 prescriptions and refills. In total Dean K Naritoku wrote 1,295 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 159 | 384 | 44 | $8,425 |
| Xcopri Cenobamate | 108 | 122 | 13 | $165K |
| Zonisamide Generic | 95 | 250 | 30 | $5,839 |
| Oxcarbazepine Generic | 94 | 214 | 27 | $14K |
| Aptiom Eslicarbazepine Acetate | 87 | 129 | 16 | $235K |
| Lamotrigine Generic | 83 | 204 | 18 | $2,163 |
| Fycompa Perampanel | 75 | 89 | 11 | $106K |
| Topiramate Generic | 55 | 149 | 17 | $740 |
| Phenobarbital Generic | 40 | 48 | Under 11 | $613 |
| Divalproex Sodium Generic | 39 | 105 | Under 11 | $3,217 |
| Lacosamide Generic | 38 | 68 | Under 11 | $5,060 |
| Baclofen Generic | 33 | 47 | Under 11 | $333 |
| Sumatriptan Succinate Generic | 29 | 31 | Under 11 | $263 |
| Briviact Brivaracetam | 29 | 29 | Under 11 | $47K |
| Clonazepam Generic | 25 | 25 | Under 11 | $64.5 |
Brand drugs: 378 claims; generic drugs: 877 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dean K Naritoku $4,008 ($4,008 in general payments such as food, travel and fees) from 26 companies. The largest payer was SK Life Science, Inc. with $2,219.
| Company | Payments | Amount |
|---|---|---|
| SK Life Science, Inc. | 13 | $2,219 |
| UCB, Inc. UCB.BR | 12 | $304 |
| Abbvie Inc. ABBV | 14 | $270 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $116 |
| ACADIA Pharmaceuticals Inc ACAD | 4 | $96.27 |
| Ceribell, Inc. CBLL | 1 | $91.73 |
| Genentech USA, Inc. ROG.SW | 4 | $90.8 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $76.44 |
| Eisai Inc. 4523.T | 4 | $72.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.